Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Riovant in plans to sell UC drug to Roche for US$7 Billion

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jul 14, 2023 10:13am

216 Views

Post# 35541044

Riovant in plans to sell UC drug to Roche for US$7 Billion

July 14, 2023 - Riovant in discussions to sell its single-agent experimental ulcerative colitis drug RVT-3101 for 7 billion dollars, less than a year after acquiring the program from Pfizer.

https://www.wsj.com/articles/roivant-in-talks-to-sell-stomach-drug-to-roche-in-deal-valued-at-more-than-7-billion-c68e3f3f

https://investor.roivant.com/news-releases/news-release-details/roivant-reports-chronic-period-data-rvt-3101-tuscany-2-phase-2b

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing